menu
    • menu

    Company profile for Insignis Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Dr. Zhang is the founder and CEO of Insignis Therapeutics Inc., a specialty pharmaceutical company dedicated to developing and commercializing a convenient oral epinephrine tablet formulation for emergency treatment of anaphylaxis, a life-threatening allergy. Dr. Zhang also serves as president of 3RServices LLC, a drug development CRO he founded in 2013 to help pharmaceutical/biotech companies translating novel scientific disc...
    Dr. Zhang is the founder and CEO of Insignis Therapeutics Inc., a specialty pharmaceutical company dedicated to developing and commercializing a convenient oral epinephrine tablet formulation for emergency treatment of anaphylaxis, a life-threatening allergy. Dr. Zhang also serves as president of 3RServices LLC, a drug development CRO he founded in 2013 to help pharmaceutical/biotech companies translating novel scientific discoveries into important medical cures. Over his pharmaceutical career, Dr. Zhang has played key roles in advancing multiple drug candidates into clinical trials.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Insignis TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    410 Sackett Point Rd., Bldg. 20, North Haven, Connecticut, 06473
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.insignisrx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/insignisrx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Insignis Therapeutic Receives FDA Feedback on IN-001 Program
    Insignis Therapeutic Receives FDA Feedback on IN-001 Program

    05 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/05/2974868/0/en/Insignis-Therapeutics-Receives-Positive-FDA-Feedback-on-IN-001-Clinical-Program-for-Needle-Free-Anaphylaxis-Treatment.html

    GLOBENEWSWIRE
    05 Nov 2024
    Share Share
    Insignis Reports Positive Phase 1 Results For Epinephrine Spray
    Insignis Reports Positive Phase 1 Results For Epinephrine Spray

    07 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/07/2958883/0/en/Insignis-Therapeutics-Announces-Positive-Results-from-Phase-1-Clinical-Study-of-IN-001-Liquid-Epinephrine-Sublingual-Spray-for-Anaphylaxis.html

    GLOBENEWSWIRE
    07 Oct 2024
    Share Share
    Insignis Therapeutics Gets FDA Fast Track For IN-001 In Anaphylaxis
    Insignis Therapeutics Gets FDA Fast Track For IN-001 In Anaphylaxis

    13 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/13/2929089/0/en/Insignis-Therapeutics-Receives-FDA-Fast-Track-Designation-for-IN-001-for-Anaphylaxis-Treatment.html

    GLOBENEWSWIRE
    13 Aug 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search